Ticlopidine (250 mg twice daily) was administered to human volunteers for seven days
and the response of their heparinized platelet-rich plasma to SKNMC (ADP-dependent)
human neuroblastoma cells was examined. The first wave of platelet aggregation, characteristic
of ADP-dependent human tumor cell lines, was completely abolished but was replaced
by a lag period prior to the onset of aggregation. In the Baumgartner perfusion apparatus
there was a marked inhibition in the thrombus generated by the presence of SKNMC cells
with a concomitant increase in the percentage of surface coverage. These results suggest
that the administration of ticlopidine could be useful to prevent some of the steps
of metastatic dissemination in which activated platelets may play a role.
Keywords
Platelet activation - Human neuroblastoma - Ticlopidine Summary
